A304840 Stock Overview
PeopleBio, Inc., a biotech company, develops bioproducts for diagnostic and treatment of protein misfolding diseases.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
PeopleBio, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩2,715.00 |
| 52 Week High | ₩11,466.67 |
| 52 Week Low | ₩2,610.00 |
| Beta | 0.84 |
| 1 Month Change | -9.20% |
| 3 Month Change | -8.74% |
| 1 Year Change | -72.03% |
| 3 Year Change | -87.17% |
| 5 Year Change | n/a |
| Change since IPO | -72.15% |
Recent News & Updates
Recent updates
Shareholder Returns
| A304840 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | -1.6% | 4.2% | 0.8% |
| 1Y | -72.0% | 7.3% | 6.3% |
Return vs Industry: A304840 underperformed the KR Biotechs industry which returned 7.3% over the past year.
Return vs Market: A304840 underperformed the KR Market which returned 6.3% over the past year.
Price Volatility
| A304840 volatility | |
|---|---|
| A304840 Average Weekly Movement | 4.3% |
| Biotechs Industry Average Movement | 7.8% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in KR Market | 11.7% |
| 10% least volatile stocks in KR Market | 2.3% |
Stable Share Price: A304840 has not had significant price volatility in the past 3 months.
Volatility Over Time: A304840's weekly volatility has decreased from 10% to 4% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 71 | Sungmin Kang | www.peoplebio.net |
PeopleBio, Inc., a biotech company, develops bioproducts for diagnostic and treatment of protein misfolding diseases. Its Multimer Detection System technology uses capturing antibodies and epitope-overlapping detection antibodies for the detection of oligomers or multimers from monomers in protein-misfolding diseases. PeopleBio, Inc. was founded in 2002 and is based in Seongnam, South Korea.
PeopleBio, Inc. Fundamentals Summary
| A304840 fundamental statistics | |
|---|---|
| Market cap | ₩57.10b |
| Earnings (TTM) | -₩16.03b |
| Revenue (TTM) | ₩4.45b |
12.8x
P/S Ratio-3.6x
P/E RatioIs A304840 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A304840 income statement (TTM) | |
|---|---|
| Revenue | ₩4.45b |
| Cost of Revenue | ₩3.08b |
| Gross Profit | ₩1.38b |
| Other Expenses | ₩17.41b |
| Earnings | -₩16.03b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -762.41 |
| Gross Margin | 30.90% |
| Net Profit Margin | -360.10% |
| Debt/Equity Ratio | 6.8% |
How did A304840 perform over the long term?
See historical performance and comparison